Inogen to Announce Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 27, 2018

The Company will host a corresponding conference call beginning at 1:30 p.m. PT/4:30 p.m. ET.

Jan. 24, 2018 21:03 UTC

GOLETA, Calif.--(BUSINESS WIRE)--Inogen (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release fourth quarter and full year 2017 financial results after market close on Tuesday, February 27, 2018. The Company will host a corresponding conference call beginning at 1:30 p.m. PT/4:30 p.m. ET.

Individuals interested in listening to the conference call may do so by dialing (855) 238-8123 for domestic callers or (412) 317-5217 for international callers. Please reference Inogen (INGN) to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen’s website at: http://investor.inogen.com/.

A replay of the call will be available beginning, February 27, 2018 at 3:30 p.m. PT/6:30 p.m. ET through 3:30 p.m. PT/6:30 p.m. ET on March 6, 2018. To access the replay, dial (877) 344-7529 or (412) 317-0088 and reference Access Code: 10116324. The webcast will also be available on Inogen’s website for one year following the completion of the call.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.

About Inogen

Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

For more information, please visit www.inogen.com.

Contacts

Inogen, Inc.
Investor Relations Contact:
Matt Bacso, CFA
805-879-8205
or
Media Contact:
Byron Myers
805-562-0503

Source: Inogen, Inc.

MORE ON THIS TOPIC